ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the drug ZD1839 (Iressa) can shrink
or slow the growth of cancer in participants with recurrent and/or metastatic squamous cell
cancer (SCC) of the skin. The safety of this drug will also be studied.